Sean Ainsworth

Sean Ainsworth, CEO and Chairman of Immusoft, shares his experiences transitioning from a lab to biotech entrepreneurship. He discusses the promise of engineered B cell therapies for lysosomal storage diseases, highlighting the benefits over traditional enzyme replacement therapies. Ainsworth delves into his journey through M&A, the future of gene therapies, and regulatory frameworks. He also elaborates on the streamlined patient experience of his therapies, aiming for safer, redosable options, and advancing candidate indications.